Skip to main content

Table 1 Patient characteristics

From: Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

  Age (years) Weight (kg) Sex Race APACHE II SOFA Voriconazole indication
Mean ± SD 53 ± 11 81 ± 14 50% Male 70% White 32 ± 4 16 ± 4 Pulmonary aspergillosis (n = 4)
10% Asian Empiric broad spectrum antifungal (n = 4)
Median (range) 55 (33–70) 83 (54–100)   10% Hispanic/White 31 (27–38) 17 (9–20) Scedosporium brain abscess (n = 1)
10% Native American Candida glabrata peritonitis (n = 1)
  1. Data are presented as mean ± standard deviation (SD); median (minimum to maximum range); or numbers/proportions. APACHE II, Acute Physiologic and Chronic Health Evaluation II score; SOFA, Sequential Organ Failure Assessment score.